Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis

References

• Hussain S, Dreyfus DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant. 2003;18(11):2364–2368. doi:10.1093/ndt/gfg41314551367
   PubMed Web of Science ®Google Scholar
• Ritz E, Dikow R, Adamzcak M, et al. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients[C]//Seminars in dialysis. Blackwell Sci Inc. 2002;15(3):135–140.
   Google Scholar
• Ritz E, Dikow R, Adamzcak M, et al. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients[C]//Seminars in dialysis. Malden, US: Blackwell Sci Inc. 2002;15(3):135–140.
   Google Scholar
• Szczech LA, Reddan DN, Owen WF Jr, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 2001;60(1):292–299. doi:10.1046/j.1523-1755.2001.00799.x11422764
   PubMed Web of Science ®Google Scholar
• Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation. 2002;106(17):2207–2211.12390949
   PubMed Web of Science ®Google Scholar
• Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799–805. doi:10.1056/NEJM1998091733912039738087
   PubMed Web of Science ®Google Scholar
• Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36(2):286–290.2528654
   PubMed Web of Science ®Google Scholar
• Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38(4):S26–S29. doi:10.1053/ajkd.2001.27392
   PubMed Web of Science ®Google Scholar
• Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999;12(9):867–873.10509543
   PubMed Web of Science ®Google Scholar
• Clark BA, Shannon C, Brown RS, Gervino EV. Extrarenal potassium homeostasis with maximal exercise in end-stage renal disease. J Am Soc Nephrol. 1996;7(8):1223–1227.8866416
   PubMed Web of Science ®Google Scholar
• Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2(1):47–54.8798105
   PubMedGoogle Scholar
• Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40(1):28–33.12105134
   PubMed Web of Science ®Google Scholar
• Bader M. Role of the local renin–angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol. 2002;34(11):1455–1462.12431444
   PubMed Web of Science ®Google Scholar
• Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663–670. doi:10.1016/j.cardiores.2003.11.03714985063
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35(1):30–34.9302344
   PubMed Web of Science ®Google Scholar
• Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19(9):1371–1376.9792263
   PubMed Web of Science ®Google Scholar
• Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31(1):451–458.9453344
   PubMed Web of Science ®Google Scholar
• Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens. 2000;14(2):83. doi:10.1038/sj.jhh.100094910723112
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity. Cardiovasc Drugs Ther. 1996;10(5):511–518.8950064
   PubMed Web of Science ®Google Scholar
• MacKenzie SM, Clark CJ, Fraser R, et al. Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol. 2000;24(3):321–328.10828825
   PubMed Web of Science ®Google Scholar
• Bonvalet JP, Alfaidy N, Farman N, Lombès M. Aldosterone: intracellular receptors in human heart. Eur Heart J. 1995;16(suppl_N):92–97.
   PubMed Web of Science ®Google Scholar
• Kornel L. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens. 1994;7(1):100–103.8136102
   PubMed Web of Science ®Google Scholar
• Coirini H, Mari A, De Nicola AF, et al. Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro. Brain Res. 1985;361(1–2):212–216.2935223
   PubMed Web of Science ®Google Scholar
• Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–18. doi:10.1056/NEJM1996010433401037494564
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103(1):72–77.11136688
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biochem Physiol. 1994;269(39):24316–24320.
   Google Scholar
• Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep. 2003;5(5):408–417.12948434
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM19990902341100110471456
   PubMed Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102(22):2700–2706.11094035
   PubMed Web of Science ®Google Scholar
• Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107(20):2559–2565. doi:10.1161/01.CIR.0000068340.96506.0F12732605
   PubMed Web of Science ®Google Scholar
• Dong Q, Liu K-S, Liu H-B, et al. Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction. Chin J Cardiol. 2005;33(4):315–319.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.100010019621070
   PubMed Web of Science ®Google Scholar
• Taggart DP, DAmico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001;358:870–875. doi:10.1016/S0140-6736(01)06069-X11567701
   PubMed Web of Science ®Google Scholar
• Athanasiou T, Al-Ruzzeh S, Kumar P, et al. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients. Ann Thorac Surg. 2004;77:745–753. doi:10.1016/S0003-4975(03)01431-014759484
   PubMed Web of Science ®Google Scholar
• Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51–61. doi:10.1258/135581902192767411822262
   PubMedGoogle Scholar
• Hase M, Babazono T, Ujihara N, Uchigata Y. Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Investig. 2013;4(3):316–319. doi:10.1111/jdi.12029
   PubMed Web of Science ®Google Scholar
• Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic hemodialysis patients. Nephrol Dial Transplant. 2003;18(11):2359–2363. doi:10.1093/ndt/gfg38814551366
   PubMed Web of Science ®Google Scholar
• Liang Y. The effects of spironolactone on LVEF and LVM in heamodialysis patients with end stage renal disease. Chin J Clinicians(Electronic Edition). 2011;18:5271–5275.
   Google Scholar
• Lin CT, Zhang Q, Zhang HF, et al. Long‐term effects of low‐dose spironolactone on chronic dialysis patients: a randomized placebo‐controlled study. J Clin Hypertens. 2015.
   Web of Science ®Google Scholar
• Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63(6):528–536. doi:10.1016/j.jacc.2013.09.05624184249
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens. 2014;16(9):658–663. doi:10.1111/jch.12374
   Web of Science ®Google Scholar
• Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. N Engl J Med. 2009;20(3):392.
   Google Scholar
• Feniman-De-Stefano GMM, Zanati-Basan SG, De Stefano LM, et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis. 2015;9(4):158–167. doi:10.1177/175394471559144826116627
   PubMedGoogle Scholar
• Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005;46(1):94–101.15983962
   PubMed Web of Science ®Google Scholar
• Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1380–1387. doi:10.2215/CJN.0942120920522535
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321. doi:10.1056/NEJMoa03020712668699
   PubMed Web of Science ®Google Scholar
• Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001;141(1):41–46. doi:10.1067/mhj.2001.11125811136485
   PubMed Web of Science ®Google Scholar
• Ng KP, Arnold J, Sharif A, et al. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: a systematic review and meta-analysis of randomized trials. J Renin Angiotensin Aldosterone Syst. 2015;1470320315575849.
   Web of Science ®Google Scholar
• Choi HY, Ha SK. Potassium balances in maintenance hemodialysis. Electrolyte Blood Press. 2013;11(1):9–16. doi:10.5049/EBP.2013.11.1.923946760
   PubMedGoogle Scholar
• Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56(2):338–347. doi:10.1053/j.ajkd.2010.03.02220580474
   PubMed Web of Science ®Google Scholar
• Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291–297.12967694
   PubMed Web of Science ®Google Scholar
• Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness a systematic review and meta-analysis. Circulation. 2007;115(4):459–467. doi:10.1161/CIRCULATIONAHA.106.62887517242284
   PubMed Web of Science ®Google Scholar
• O‘Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340(1):14–22. doi:10.1056/NEJM1999010734001039878640
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Vemmos K, Papamichael C, et al. Common carotid artery intima-media thickness and the risk of stroke recurrence. Stroke. 2006;37(7):1913–1916. doi:10.1161/01.STR.0000226399.13528.0a16728693
   PubMed Web of Science ®Google Scholar
• Hammer F, Krane V, Stork S, et al. Rationale and design of the mineralocorticoid receptor antagonists in end-stage renal disease study (MiREnDa). Nephrol Dial Transplant. 2014;29(2):400–405. doi:10.1093/ndt/gft40924166468
   PubMed Web of Science ®Google Scholar